growth-hormone
Low stock
CJC-1295 (No DAC) 5mg
$45.00
growth-hormone
Tesamorelin 5mg
For in vitro research only
A stabilized GHRH(1-44) analog supplied as a 5 mg lyophilized vial for research into growth-hormone-releasing hormone signaling, the GH/IGF-1 axis, and visceral adiposity.
Third-party testedView certificate
$45.00
- Free shipping from $300
- Same-day shipping — order before 1 PM
- Secure payment
Promotion
Free 3 ml bacteriostatic water with every order.
Everything you need to start is included.
New
Advanced lab tests
HPLC tests
Endotoxin assay
TYMC test
TAMC test
Heavy metals screening
Technical specification
- Molecular formula
- C₂₂₁H₃₆₆N₇₂O₆₇S
- Molar mass
- 5135.9 g/mol
- Purity
- ≥99%
- Synonyms
- TH9507
- Solubility
- Water-soluble (reconstitute with bacteriostatic water)
- Organoleptic profile
- White to off-white lyophilized powder
- Composition
- Synthetic peptide — requires reconstitution
Key attributes
Kit contents
- 1 × Tesamorelin 5mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
Each vial is intended for laboratory research use only and is not for human or veterinary use.
Research usage
How is Tesamorelin 5mg used in research?
Tesamorelin is a synthetic, stabilized analog of human growth-hormone-releasing hormone (GHRH 1-44), modified with a trans-3-hexenoyl group to resist enzymatic degradation and extend its research half-life. It is investigated as an agonist of the GHRH receptor, where it is reported to stimulate the endogenous, pulsatile release of growth hormone from the pituitary in preclinical models. Research has centered on its influence over the GH/IGF-1 axis and downstream effects on lipid and visceral-adipose-tissue metabolism. Because of this mechanism, it is frequently studied as a tool compound for exploring somatotropic signaling and adiposity in animal research models.
Research reports that Tesamorelin binds the GHRH receptor and increases the pulsatile secretion of growth hormone, with corresponding elevations in IGF-1 observed in preclinical models. Studies have investigated its association with reductions in visceral adipose tissue and changes in lipid profiles within animal research models. Its resistance to enzymatic cleavage is reported to confer greater stability than native GHRH, an attribute of interest for sustained-signaling investigations. These characteristics have positioned it as a subject of interest in metabolic and endocrine research models.
The full pharmacological and toxicological profile of Tesamorelin has not been completely characterized in research models. Observations reported in preclinical and research settings include injection-site reactions and effects related to modulation of the GH/IGF-1 axis, and the material should be handled only by qualified personnel using appropriate laboratory practices and protective equipment. As with all lyophilized research peptides, contact, inhalation, and ingestion should be avoided. This material is not for human or veterinary use and is intended strictly for in vitro and preclinical research.
Recommended ratio
- 2 mL of bacteriostatic water per 5 mg vial
- Equivalent to 2.5 mg/mL (i.e. 0.25 mg per 10 units on a 100 U insulin syringe)
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Unopened / before reconstitution
- Store refrigerated (2 °C – 8 °C).
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Stable for 28 to 30 days.
- Avoid exposure to light and excessive heat.
Related research peptides.
See the protocol
growth-hormone
Ipamorelin 5mg
$50.00
growth-hormone
AOD-9604 10mg
$85.78
growth-hormone
Tesamorelin 10mg
$84.64